logo-loader

Full interview: Algernon Pharmaceuticals receives positive feedback from Health Canada for Ifenprodil

Published: 19:26 08 Apr 2020 EDT

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss the company receiving positive feedback from Health Canada on the Company’s plan for a Phase Two COVID-19 clinical study in Canada, with its repurposed drug Ifenprodil. Moreau explains what that study will look like and he also discusses a similar program in South Korea.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

13 hours, 17 minutes ago